Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women

Summary The final analysis of this 2-year, randomized, crossover study showed that postmenopausal women with osteoporosis were more adherent, compliant, and persistent with subcutaneous denosumab injections every 6 months than with once-weekly alendronate tablets. After receiving both treatments, wo...

Full description

Saved in:

Bibliographic Details
Published in:	Osteoporosis international Vol. 23; no. 1; pp. 317 - 326
Main Authors:	Freemantle, N., Satram-Hoang, S., Tang, E.-T., Kaur, P., Macarios, D., Siddhanti, S., Borenstein, J., Kendler, D. L.
Format:	Journal Article
Language:	English
Published:	London Springer-Verlag 01.01.2012 Springer Nature B.V
Subjects:	Administration, Oral Aged Alendronate - administration & dosage Alendronate - adverse effects Alendronate - therapeutic use Alendronic acid Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Bisphosphonates Bone Density - drug effects Bone Density Conservation Agents - administration & dosage Bone Density Conservation Agents - adverse effects Bone Density Conservation Agents - therapeutic use Bone mineral density Clinical trials Comparative studies Cross-Over Studies Denosumab Drug Administration Schedule Drug therapy Endocrinology Female Humans Injections, Subcutaneous Medication Adherence Medicine Medicine & Public Health Middle Aged Original Original Article Orthopedics Osteoporosis Osteoporosis, Postmenopausal - drug therapy Osteoporosis, Postmenopausal - physiopathology Patient Preference Post-menopause RANK Ligand - antagonists & inhibitors Rheumatology Tablets Treatment Outcome Womens health Adherence Persistence Alendronate Compliance Denosumab
ISSN:	0937-941X, 1433-2965, 1433-2965
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!